"Shareholders in Hemispherx Biopharma, Inc. (AMEX: HEB) have been waiting a considerable period of time for the specialty pharmaceutical company to deliver positive news regarding their Phase III trial involving the experimental therapeutic Ampligen."
Read more: With New Information Indicating Effectiveness of Ampligen:
No comments:
Post a Comment